London Co. of Virginia Buys 6,111 Shares of Haemonetics Co. (NYSE:HAE)

London Co. of Virginia increased its stake in shares of Haemonetics Co. (NYSE:HAE) by 2.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 281,738 shares of the medical instruments supplier’s stock after purchasing an additional 6,111 shares during the quarter. London Co. of Virginia’s holdings in Haemonetics were worth $21,998,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. TD Waterhouse Canada Inc. purchased a new position in Haemonetics during the fourth quarter worth $25,000. Covestor Ltd lifted its stake in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new position in shares of Haemonetics during the fourth quarter valued at approximately $62,000. Parkside Financial Bank & Trust raised its holdings in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 240 shares during the period. Finally, AlphaQuest LLC lifted its stake in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 1,826 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 0.3%

Haemonetics stock opened at $68.21 on Monday. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $97.97. The stock has a market capitalization of $3.43 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The business has a 50 day simple moving average of $62.75 and a 200-day simple moving average of $71.36.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.02. The company had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.90 EPS. On average, analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on HAE. Raymond James reiterated a “strong-buy” rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday. JMP Securities decreased their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research cut their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, StockNews.com raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.